Aditxt Announces Partnership Agreements with Appili Therapeutics and Evofem Biosciences

Aug 29, 2024•over 1 year ago

Contract Type

partnership

RichmondHealth Care

Description

Aditxt, Inc. announced its partnership agreements with Appili Therapeutics, Inc. and Evofem Biosciences, Inc. at the H.C

Company Information

Company

Aditxt

Location

737 N. FIFTH STREET

Richmond, Virginia, United States

About

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.

Related People

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months